Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer

Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its relationship to molecularly defined subsets, we analyzed BGN expression by immunohistochemistry on a tissue microarray c...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Neoplasia
Hoofdauteurs: Jacobsen, Frank, Kraft, Juliane, Schroeder, Cornelia, Hube-Magg, Claudia, Kluth, Martina, Lang, Dagmar S., Simon, Ronald, Sauter, Guido, Izbicki, Jakob R., Clauditz, Till S., Luebke, Andreas M., Hinsch, Andrea, Wilczak, Waldemar, Wittmer, Corinna, Büscheck, Franziska, Höflmayer, Doris, Minner, Sarah, Tsourlakis, Maria Christina, Huland, Hartwig, Graefen, Markus, Budäus, Lars, Thederan, Imke, Salomon, Georg, Schlomm, Thorsten, Melling, Nathaniel
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Neoplasia Press 2017
Onderwerpen:
Original article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5565634/
https://ncbi.nlm.nih.gov/pubmed/28830008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2017.06.003
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items